Novo Nordisk ... calorie diet and increased physical activity for weight management in obese adults, as well as heavily overweight people with a weight-related problem such as diabetes, high ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

Novo Nordisk said its diabetes pill Rybelsus showed cardiovascular ... health care providers' recommendations to eat a healthy diet, get regular physical activity and take their medications ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Novo Nordisk A/S is partnering with U.S. biotech ... that use different ways to potentially treat obesity, Type 2 diabetes and other diseases linked to obesity, the Danish maker of blockbuster ...

COPENHAGEN (Reuters) -Novo Nordisk (NVO) has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other ...

As a pioneer in diabetes care, Novo has been in the business for more than 85 years and claims 30% of the $50 billion-plus diabetes treatment market and roughly half of the $20 billion insulin market.

Novo Nordisk A/S’s (NYSE:NVO) shared data Friday on its kidney outcomes trial, FLOW. The trial evaluated once-weekly injectable Ozempic for the treatment of type 2 diabetes. The FLOW (Evaluate ...